Harbin Gloria Pharmaceuticals (002437) — Tangible Net Worth Ratio
Harbin Gloria Pharmaceuticals (002437) has a Tangible Net Worth Ratio of 93.2% as of March 2026. This metric is calculated by deducting intangible assets (CN¥162.65 Million) from net assets (CN¥2.41 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See how liquid is Harbin Gloria Pharmaceuticals's working capital to evaluate short-term liquidity relative to the company's equity base.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Harbin Gloria Pharmaceuticals Tangible Net Worth Ratio (2007–2025)
This chart shows how Harbin Gloria Pharmaceuticals's Tangible Net Worth Ratio has changed across 19 annual periods from 2007 to 2025. As of March 2026, the ratio stands at 93.2%, reflecting net assets of CN¥2.41 Billion with intangible assets of CN¥162.65 Million CNY. See 002437 days of operational coverage to measure how many days the company can operate on defensive assets alone.
Annual Tangible Net Worth Ratio for Harbin Gloria Pharmaceuticals (2007–2025)
The table below presents the year-by-year Tangible Net Worth Ratio for Harbin Gloria Pharmaceuticals from 2007 to 2025, covering 19 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see Harbin Gloria Pharmaceuticals stock valuation.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 92.6% | CN¥2.31 Billion | CN¥170.95 Million | CN¥3.13 Billion | ▲ +1.8 pp |
| 2024 | 90.8% | CN¥1.97 Billion | CN¥181.11 Million | CN¥2.83 Billion | ▲ +2.5 pp |
| 2023 | 88.3% | CN¥1.71 Billion | CN¥199.53 Million | CN¥3.15 Billion | ▲ +1.6 pp |
| 2022 | 86.8% | CN¥1.70 Billion | CN¥225.69 Million | CN¥4.07 Billion | ▲ +1.7 pp |
| 2021 | 85.0% | CN¥1.98 Billion | CN¥296.70 Million | CN¥4.70 Billion | ▲ +3.4 pp |
| 2020 | 81.6% | CN¥1.93 Billion | CN¥355.15 Million | CN¥4.52 Billion | ▲ +9.0 pp |
| 2019 | 72.6% | CN¥1.59 Billion | CN¥435.16 Million | CN¥6.41 Billion | ▼ -13.3 pp |
| 2018 | 85.9% | CN¥4.39 Billion | CN¥618.18 Million | CN¥9.48 Billion | ▲ +2.5 pp |
| 2017 | 83.4% | CN¥4.25 Billion | CN¥706.34 Million | CN¥9.06 Billion | ▼ -5.2 pp |
| 2016 | 88.6% | CN¥4.05 Billion | CN¥462.29 Million | CN¥8.67 Billion | ▲ +2.5 pp |
| 2015 | 86.1% | CN¥3.47 Billion | CN¥482.28 Million | CN¥8.32 Billion | ▼ -0.9 pp |
| 2014 | 87.0% | CN¥3.10 Billion | CN¥403.55 Million | CN¥4.92 Billion | ▲ +2.6 pp |
| 2013 | 84.4% | CN¥2.48 Billion | CN¥387.73 Million | CN¥2.94 Billion | ▼ -11.5 pp |
| 2012 | 95.9% | CN¥2.36 Billion | CN¥97.33 Million | CN¥2.56 Billion | ▼ -0.6 pp |
| 2011 | 96.4% | CN¥2.20 Billion | CN¥78.42 Million | CN¥2.31 Billion | ▼ -2.0 pp |
| 2010 | 98.5% | CN¥2.12 Billion | CN¥32.28 Million | CN¥2.19 Billion | ▲ +6.0 pp |
| 2009 | 92.5% | CN¥287.53 Million | CN¥21.61 Million | CN¥442.48 Million | ▲ +2.6 pp |
| 2008 | 89.9% | CN¥194.04 Million | CN¥19.58 Million | CN¥279.21 Million | ▲ +3.4 pp |
| 2007 | 86.5% | CN¥138.36 Million | CN¥18.65 Million | CN¥215.51 Million | — |